Shanghai Reinovax Biologics Co.,ltd

This early-stage study tests a new vaccine (PCV24) designed to protect children from 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. About 230 healthy children aged 2 months to 17 years will receive the vaccine or a placebo to …

This study tests a new vaccine designed to protect adults aged 18 and older against 24 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 992 participants will receive the vaccine to check its safety and how well it triggers the immune system. …